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sAntagonism of miR-33 in Mice Promotes Reverse Cholesterol Trans-
port and Regression of Atherosclerosis
Rayner KJ, Sheedy FJ, Esau CC, et al. J Clin Invest 2011;121:2921-31.
Conclusion: Anti-miR33 oligonucleotide treatment promotes reverse
cholesterol transport and regression of atherosclerosis.
Summary: For every 1% increase in circulating HDL cholesterol
(HDL-C), there is a 2% decrease in overall risk for development of coronary
artery disease (Wilson PW. Am J Cardiol 1990;66:7A-10A). It has been
found in mouse models of atherosclerosis that over expression of apoA1,
which increases HDL levels, hinders plaque progression and promotes
plaque regression (Plump AS, et al. Proc Natl Acad Sci USA 1994;91:
9607-11 and Rong JX, et al. Circulation 2001;104:2447-52). Such evi-
dence has stimulated an interest in therapies to raise HDL levels. Despite the
fact HDL raising strategies may be effective therapy for atherosclerosis, the
underlying mechanisms that contribute to HDL regulation and its manip-
ulation for therapy remain poorly understood.
Recent advances in lipid metabolism reveal that miR-33, and intronic
microRNA within the SREBF 2 gene, suppresses expression of the ABC
cholesterol transporter and decreases circulatingHDL levels. This suggests a
possible strategy of antagonism of miR-33 to be atheroprotective. The
authors assessed the impact of miR-33 in mice deficient for the LDL
receptor (LDLR-/-mice) who had established atherosclerotic plaque. With 4
weeks of treatment of anti miR-33, there was increased circulating HDL
levels and enhanced reverse cholesterol transport to the plasma, liver, and
feces. Anti miR-33-treated mice showed reduction in plaque size and lipid
content. They also demonstrated increased markers of plaque stability and
decreased inflammatory gene expression. Anti miR-33 raised ABCA1 levels
in the liver. Anti miR-33 olgonucleotides directly targeted plaque macro-
phages and enhanced ABCA1 expression and cholesterol removal.
Comment: This study demonstrates that HDL generated by antago-
nism of miR-33 is functional and promotes removal of excess cholesterol
from atherosclerotic plaques into the reverse cholesterol transport pathway
thereby allowing for cholesterol excretion. Other effects of anti-miR33
included reduction in the lesion area, macrophage number, lipid content,
and inflammatory gene expression. The study demonstrates for the first time
that olgonucleotides can penetrate atherosclerotic plaque, reach lesion mac-
rophages, and enhance cholesterol removal. All of this could eventually
result in clinically relevant regression of atherosclerosis.
Decreased Kidney Function an Unrecognized and Often Untreated
Risk Factor for Secondary Cardiovascular Events After Carotid
Surgery
Van Lammeren GW, Moll FL, Blakestijn PJ, et al. Stroke 2011;42:307-12.
Conclusions: Patients with moderate kidney failure have an increased
risk of cardiovascular death and an increased risk of myocardial infarction 3
years after carotid endarterectomy (CEA) compared with patients with
normal or mild renal impairment.
Summary:The prevalence of chronic kidney disease (CKD) in the US
is currently estimated to be 9.6% of the population (Coresh J, et al. J Am Soc
Nephrol 2005;16:180-8) and increasing. Impaired kidney function in-
creases risk of death and hospitalization, and while CKD is irreversible, it is
treatable. Angiotensin-converting enzyme inhibitors (ACE inhibitors) and
angiotensin II antagonists can delay progression of CKD (Brenner BM, et al.
N Engl J Med 2001;345:861-9). This study sought to assess cardiovascular
mortality andmorbidity following carotid endarterectomy (CEA) in patients
with moderate kidney failure and to determine what proportion of patients
with moderate kidney failure receive optimal medical treatment or undergo
workup of their renal failure prior to CEA.
There were 1085 patients who underwent CEA between 2002 and
2009 who were included in the study. Baseline estimated glomerular filtra-
tion rate (eGFR) was assessed, and eGFR of 30-59 was defined as moderate
kidney failure. Patients with moderate kidney failure were compared with
those with normal or mildly reduced kidney function (eGFR60). Primary
endpoints were cardiovascular death (fatal myocardial infarction, fatal
stroke, and ruptured abdominal aortic aneurysm). Secondary endpoints
were cardiovascular morbidity. In this study population, 26.5% (n 288) of
the patients had moderate kidney failure. Median follow-up was 2.95 years
(0 to 3.0 years). The adjusted hazard ratio for cardiovascular death with
moderate kidney failure was 2.22 (1.27-3.89). The adjusted hazard ratio for
myocardial infarction with moderate kidney failure was 1.90 (1.04 to 3.47).
There was no increased rate of peripheral interventions or stroke in the
patients with moderate kidney failure. Of the patients with moderate kidney
g
Aailure, 38.3% (105/274) received ACE inhibitors. Only 34.4% had visited a
ephrologist and 75% had received statins.
Comment: The short-term risk of moderate kidney failure is largely
nrecognized by many surgeons. There are no widespread formal screening
rograms for moderate kidney failure, but all vascular surgery patients
ndergo basic metabolic testing and therefore, in essence, are screened for
nderlying kidney disease. Based on these data, vascular surgeons should
onsider referral to a nephrologist for any patient they identify with even
oderate renal insufficiency.
DL Promotes Rapid Atherosclerosis Regression in Mice and Alters
nflammatory Properties of Plaque Monocyte-Derived Cells
eig JE, Rong JX, Shamir R, et al. PNAS 2011;108:7166-71.
Conclusion: HDL cholesterol (HDL-C) is an in vivo regulator of
igratory and inflammatory properties of monocyte- derived cells in mouse
therosclerotic plaques.
Summary: There is an inverse relationship between HDL-C and
ardiovascular risk. HDL-C has been shown to be atheroprotective in mouse
odels of atherosclerosis (Rubin EM. Nature 1991;353:265-7). Infusion of
DL-C into human subjects has been shown to reduce plaque size (Nissen
E. JAMA 2003;290:2292-300). The authors, therefore, postulated
DL-C may be an effective therapy to induce regression of established
therosclerosis. They sought to examine the molecular effects of HDL -C on
therosclerotic plaque cells in vivo utilizing a mouse transplantation model
f atherosclerosis (Reis ED, et al. J Vas Surg 2001;34:541-7).
Plaque bearing aortic arches from apoplipoprotein E-deficient
ApoE-/- ) mice ( low HDL-C, high non-HDL-C) were transplanted into
ice with differing levels of HDL-C and non-HDL-C (C57BL6 mice
normal HDL-C, low non HDL-C]), apoA-/- mice (low HDL-C, low non
DL-C) or apoE -/-mice transgenic for human APOAI(hAI/apoE -/-;
ormal HDL-C , high non HDL-C). In persistently elevated non HDL-C
AL/apoE -/-recipients, CD68 cell count decreased in plaques by more
han 50% 1 week after transplantation. Little change in CD68 cell content
as observed in apoAL -/-recipient mice despite low lipid levels. Immigra-
ion and induction of chemokine receptor CCR7 was associated with
ecreased content of plaque CD68 cells. In CD68cells laser captured
rom plaques, normalization of HDL-C levels led to decreased expression of
nflammatory markers related to macrophages. No beneficial changes were
bserved in apoAI -/-recipients indicating a requirement for reverse choles-
erol transport for beneficial effects of HDL-C.
Comment: Data indicate that HDL-C in vivo is a regulator of migra-
ory and inflammatory properties of monocyte-derived cells found in mouse
therosclerotic plaques. These effects were independent of plasma non-
DL-C levels. This indicates HDL-C maybe an independent therapeutic
arget to promote atherosclerotic plaque regression through a mechanism of
odifying the population of monocyte-derived cells in atherosclerotic
laques.
eta-Analysis of Postoperative Mortality After Elective Repair of
bdominal Aortic Aneurysms Detected by Screening
indholt JS, Norman PE. Brit J Surg 2011;98:619-22.
Conclusion:Men whose abdominal aortic aneurysms (AAA) are iden-
ified through screening have improved early survival following operation
ompared to men whose AAAs are detected incidentally.
Summary: An incidentally detected AAA is an AAA found in the
valuation for another medical problem. AAAs detected with screening are
etected in patients without an active medical problem. Patients with
ncidentally detected AAAs may be at increased risk for AAA surgery because
f greater age, increased comorbidities, or more anatomically complex AAAs
han those whose AAAs are detected through a screening program. The
uthors thought to compare 30-day mortality of elective AAA surgery in
en whose aneurysms were detected incidentally vs those whose were
etected by screening. The authors analyzed reports from randomized trials
f AAA screening. Reports were identified through a systematic search of
EDLINE. Four relevant trials were identified and were also supplemented
ith data from the authors home institution.Meta-analysis was preformed as
xed odd ratios (OR) with 95% competence intervals. Heterogeneity be-
ween the studies was assessed using the 2 test. In the screening studies,
here were 25 deaths (2.9 %) following elective surgery in men invited for
creening (n  858) compared with 21 deaths in 383 men in the control
roup (5.5%; OR, 0.49; 0.27 to 0.88). There were 747 screened detected
AAs with 18 deaths (2.4%) in those operated on for screened detected
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